Market Intelligence · Vaxa Scan
A Single Lens Gives You a Single Answer. That Is Rarely the Right One.
Most market reads answer one question: is this big and is it growing? Those aren't bad questions. They're just two of the questions — and stopping there has a fifty-year history of getting the resource allocation call wrong.
Why This Isn't a New Problem
In the early 1970s, General Electric needed a better way to allocate capital across more than 150 business units than the tools available at the time provided. The dominant framework then was the BCG Growth-Share Matrix — plotting each business on exactly two metrics: market growth rate and relative market share. GE, working with McKinsey, concluded that two metrics weren't enough for decisions of that size, and the two firms built what became known as the GE-McKinsey Nine-Box Matrix: a multi-factor model scoring market attractiveness across as many as nine weighted criteria — growth, profitability, competitive intensity, regulatory exposure, and barriers to entry among them — rather than growth alone.
The Nine-Box Matrix has been standard business-school and consulting curriculum for over fifty years since. The underlying argument hasn't changed: reducing a market opportunity to one or two metrics produces a real answer to a narrow question, and an unreliable answer to the actual question, which is whether to commit resources.
Market size tells you how big the room is. It doesn't tell you who's already standing in it, how fast that's changing, or whether the door you're planning to use is actually open.
What "Big and Growing" Still Misses
A market can be large and expanding and still be the wrong entry point — because the competitive field has already consolidated, because capital is flowing in faster than genuine demand, or because the specific opening a company is aiming for is structurally closed even while the category around it grows. Size and growth rate describe the room. They say nothing about who else is in it, how that's shifting, or where the actual gaps are.
A Real, Well-Documented Case
Quibi raised $1.75 billion to enter short-form mobile video — a market that was, by every conventional size-and-growth measure, both large and expanding rapidly at the time. The company shut down roughly six months after launch. Post-mortems consistently point not to market size but to the dimensions size and growth don't measure: the competitive field had already been shaped by free, ad-supported alternatives, and the specific white space Quibi was aiming for turned out not to exist in the way its business case assumed. A market can pass the size test and the growth test and still fail on every other dimension that determines whether a specific entry succeeds.
The Six Dimensions Vaxa Scan Reads
Vaxa Scan — the four-week external landscape assessment sitting under Vaxa On — extends the same multi-factor logic the Nine-Box Matrix established, purpose-built for a specific go/no-go entry decision rather than an ongoing portfolio review. Six dimensions, each answering a distinct question a size-and-growth read cannot:
How large is this market or technology, and what are the credible sizing parameters behind that number? Most market-sizing exercises collapse into a single top-down figure — total addressable market pulled from an analyst report — without testing whether that figure is built from a defensible bottom-up count of actual buyers, use cases, and willingness to pay. Magnitude asks the same question the Nine-Box Matrix's growth criterion asked in the 1970s, but treats the number itself as something to interrogate rather than accept.
Where is this market or technology in its development cycle — early formation, active growth, consolidation, or saturation? A market's stage changes what "big and growing" actually means: rapid growth early in formation reflects a small base and high uncertainty, while the same growth rate late in a category's life can reflect genuine, durable demand. Everett Rogers' diffusion-of-innovation research and the widely used technology hype-cycle concept both formalize the same underlying point — a category's stage of maturity changes the interpretation of every other metric measured against it, magnitude included.
Who is already here, what position have they taken, and how defensible is it? A market with three entrenched, well-capitalized incumbents controlling most of the available demand is a fundamentally different opportunity than the same-sized market with no clear leader — even when both score identically on size and growth. Market concentration is a measurable, well-established concept in its own right; the Herfindahl-Hirschman Index, the standard concentration measure used by antitrust regulators, exists specifically because "how many real competitors, and how strong" is a distinct question from "how big is the pie."
Where is early-stage capital actually flowing, and what does that signal about where informed, risk-tolerant investors believe the category is heading? Venture funding concentration is a leading indicator precisely because it reflects a decision made before the outcome is known — investors betting real capital on a specific sub-segment before the broader market has validated it. A market that's large and growing but seeing venture capital retreat from it is telling a different story than the same market attracting new, concentrated early-stage bets.
What is the direction and pace of change, and what specifically is accelerating or constraining it? Trajectory is distinct from Maturity — a market can be in an early, immature stage while decelerating, or in a late, mature stage while re-accelerating due to a new entrant or technology shift. Momentum has a direction independent of a market's absolute stage, and that direction is what a static size-and-growth snapshot, taken at a single point in time, cannot show.
Where are the genuine gaps — unserved needs, underserved segments, positions no current participant has credibly taken? This is the dimension most directly implicated in cases like Quibi's: a market can be unambiguously large and growing while the specific gap a new entrant is aiming for turns out not to exist, because it's already served, informally or by substitutes, in a way conventional market-sizing doesn't capture. The "Blue Ocean" concept popularized by Kim and Mauborgne's research made a version of this argument at the strategy level — that the more valuable opportunities are often in uncontested space competitors have overlooked, not in the biggest slice of a contested one. White Space is the dimension that tests whether that uncontested space is real, or assumed.
01
Magnitude
How large is this market or technology, and what are the credible sizing parameters behind that number — tested against a defensible bottom-up count, not a single top-down analyst figure.
02
Maturity
Where is this market in its development cycle — early formation, active growth, consolidation, or saturation. A category's stage changes the interpretation of every other metric measured against it.
03
Corporate Participants
Who is already here, what position have they taken, and how defensible is it — market concentration is a distinct question from market size.
04
Venture Ecosystem
Where is early-stage capital actually flowing — a leading indicator because it reflects real money bet before the broader market has validated an outcome.
05
Trajectory
What is the direction and pace of change, independent of a market's absolute stage — a market can be early and decelerating, or late and re-accelerating.
06
White Space
Where are the genuine gaps — unserved needs, underserved segments, positions no current participant has credibly taken.
Why Six Scores Don't Resolve Themselves
The six dimensions don't collapse into one score, and that's deliberate. A market can read strong on Magnitude and Trajectory while reading weak on White Space — big, growing, and already spoken for — and the right call depends on which dimensions matter most for the specific decision being made, not an average across all six. Resolving that disagreement between dimensions is a judgment call, not an arithmetic one, which is what Strategic Innovation and Insights Panels are built to make.
Six Numbers Don't Add Themselves Up
The GE-McKinsey precedent is public and well documented. The six dimensions aren't a secret either — they're the stated structure of Vaxa Scan itself. What six separate scores don't do on their own is resolve a market that reads well on Magnitude and poorly on White Space into one clear go or no-go call within a four-week window. Strategic Innovation — Vaxa's methodology, built and referenced across engagements including Nokia, Intel, DuPont, and P&G — is what weighs the six against each other for a specific market and a specific client's real capability set. Insights Panels, Vaxa's proprietary primary research model, supplies the expert judgment that resolving a genuine disagreement between dimensions actually requires.
The Actual Question
The question worth asking before committing resources to a new market was never just "is this big and is it growing." It's whether all six dimensions actually agree — and if they don't, which disagreement is the one worth trusting.
It's about our Market Intelligence.
Related Material
GE-McKinsey Nine-Box Matrix — developed by McKinsey & Company for General Electric, early 1970s, as a multi-factor alternative to the BCG Growth-Share Matrix.
Rogers, E., Diffusion of Innovations, and the widely used technology hype-cycle model — on market maturity stages and their effect on interpreting growth data.
Herfindahl-Hirschman Index (HHI) — standard market concentration measure used in U.S. antitrust review. · Kim, W.C. & Mauborgne, R., Blue Ocean Strategy, Harvard Business Review Press — on identifying uncontested market space.
Quibi — widely reported post-mortem coverage of the company's 2020 launch and shutdown after approximately six months and $1.75 billion raised.